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*+ In response to epidermal growth factor (EGF) and the Ca ionophore A23187, the total phosphatidylinositides (IPr) increased in A431 human 
epidermoid carcinoma cells I .8- and 2.0-fold and in the EGF-dependent A431/Clone 15-2 cells 3.0- and 8.0-fold, respectively, over basal levels. 
Both responses were inhibited by the antiproliferative agents tyrphostins, but the EGF-induced increase in IPr was inhibited to a much greater 
extent than that induced by the ionophore. Tyrphostins which are potent EGF-receptor kinase inhibitors were also potent in blocking the EGF- 
induced production of phosphoinositides. The less potent tyrphostins were found to inhibit the EGF-dependent IPr formation more weakly. These 
results support the notion that phospholipase C is activated through its phosphorylation by the EGF receptor. 
Tyrphostins; Epidermal growth factor; Phospholipase C phosphorylation; CaZf ionophore; (A43 1 cell, A43 I /Clone 15-2 cell) 
1. INTRODUCTION 
Signal transduction in response to many hormones 
and growth factors in a variety of mitogenically respon- 
sive cell lines leads to enhanced phospholipase C (PLC)- 
catalyzed hydrolysis of phosphatidylinositol 4,5-di- 
phosphate (PIP$ to diacylglycerol (DAG) and inositol 
phosphates [I]. Inositol (1,4,5triphosphate) and DAG 
act as second messengers: the former causes the release 
of intracellular Ca2+ and the latter activates protein 
kinase C [ 1,2]. The increased cytosolic inositol 
phosphates, DAG and Ca2+ in response to receptor ac- 
tivation by the mitogen epidermal growth factor (EGF) 
[l-6] was significant in the human epidermoid car- 
cinoma cell line A43 1 [7,8], whose membranes contain 
20-50-fold the normal concentration of EGF receptors 
(EGFR) [9]. The proliferation of these cells is blocked 
by EGF, while the growth of the cell line A431/Clone 
15 is EGF-dependent [lo]. The activity of PLC im- 
munopurified from extracts of EGF-stimulated A431 
cells on Sepharose-linked antiphosphotyrosine increas- 
ed ten-fold over controls, suggesting a direct 
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biochemical link between the EGF-receptor kinase ac- 
tivity and PIPz turnover and that the EGF receptor 
directly phosphorylates PLC on tyrosine residues 
leading to its activation [ 111. The link between the 
EGFR and the phosphoinositide pathway was also sug- 
gested from studies on the kinase deficient mutant of 
the receptor. A point mutation at the ATP-binding site 
which nullifies the PTK activity of the receptor also 
abolishes the EGF-induced formation of inositol 
phosphates 1121, Indeed, Margolis et al. [13] described 
the phosphorylation of PLC-II in response to EGF and 
proposed that this event might enhance the enzymatic 
activity of PLC and concluded that the EGF-induced 
tyrosine phosphorylation of PLC-II might be an impor- 
tant regulatory link between the kinase activity of the 
EGF receptor and the hydrolysis of PIP2. Meisenhelder 
et al. [14] have described the phosphorylation of PLC- 
II (PLC y) in response to PDGF and EGF and also pro- 
posed that phosphorylation of PLC-II (PLC y) by 
PDGF and EGF receptors leads to its activation and to 
a consequent increase in PIP2 turnover. Activation of 
PLC by EGFR and PDGFR may be responsible, at least 
partially, for the mitogenic signal generated by these 
growth factors. In support of this hypothesis is the re- 
cent report that microinjection of PLC-II into NIH 3T3 
cells induces a growth and oncogenic potential in 
growth arrested fibroblast cells [ 151. 
Abbreviations: PLC, phospholipase C; PIPa, phosphatidylinositol 
4,Sdiphosphate; IPr, total phosphatidylinositides; EGF, epidermal 
growth factor; EGFR, EGF receptor; PDGF, platelet derived growth 
factor; EBSS, Earie’s basal salt solution; DMEM, Dulbecco’s 
modified Eagle’s medium; FCS, fetal calf serum 
Selective anti-proliferative compounds referred to as 
tyrphostins have been developed in our laboratory 
[ 16,171. One group, of the benzenemalononitrile fami- 
ly, is specific for the EGF-receptor kinase [17] and, 
therefore, inhibits EGF-dependent cell proliferation 
[16,18]. These compounds were also shown to inhibit 
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the phosphorylation of intracellular target proteins 
[ 181. Especially interesting was the demonstration that 
a tyrphostin such as RG50864 (AG213) inhibits the 
EGF-dependent phosphorylation of PLC-II (PLC y) in 
cells which harbor about IO6 receptors/cell [13]. In this 
communication we demonstrate that tyrphostins which 
block EGF-dependent kinase activity also block EGF- 
dependent breakdown of PIP2 strengthening the 
hypothesis that PLC-II phosphorylation by EGFR 
results in its activation. 
2. MATERIALS AND METHODS 
2.1. Materials 
EGF, Ca*+ ionophore A23187, vitamins, amino acids and Earle’s 
basal salt solution (EBSS) were purchased from Sigma Chemical Co.; 
myo-[2-3H]inositol was purchased from ARC, Inc., St. Louis, MO; 
Dowex AG 1 x 8 (200-400 mesh, formate form) was obtained from 
Bio-Rad Laboratories; Dulbecco’s modified Eagle’s medium 
(DMEM) and fetal calf serum (FCS) were from Gibco Ltd, Paisley, 
Scotland. A43lKlone 15-2 (A43l/Cll5-2) cells were a sub-clone of 
the A43l/Clone 15 cells [lo] which were a kind gift from Dr R. Bravo 
(EMBL, Heidelberg). 
2.2. Methods 
A43 1 and A43 l/C 115-2 cells were grown in 82 cm’ flasks in DMEM 
supplemented with penicillin (100 U/ml) and streptomycin (100 
pg/ml) and containing 5% or 10% inactivated (FCS) plus 100 ng/ml 
EGF, respectively. When confluent, cells were plated on 12 x 22 mm 
diameter dishes in 1.6 ml DMEM per well: 8x 104 A431 cells were 
plated in media containing 5% FCS and 2 x lo4 A43l/Cll5-2 cells 
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plated in media containing 10% fetal-calf serum and 20 ng/ml EGF. 
Two days later, when cells reached near confluence, the cells were 
washed twice with PBS and 0.8 ml inositol-free EBSS supplemented 
with vitamins and amino acids as in DMEM and containing 0.5-2,&i 
[3H]inositol/ml plus the desired concentration of tyrphostin were 
added to each well. Tyrphostins were dissolved in DMSO and then 
diluted with EBSS to a final DMSO concentration of 1.25 /l/ml. 
After 24 h, the media were washed twice with PBS and 0.8 ml fresh 
EBSS containing 100 ng/ml EGF, the desired concentration of tyr- 
phostin and 10 mM LiCl were added to each well. After 20-40 min at 
37°C 0.8 ml cold 10% TCA was added to terminate the reaction and 
total phosphatidylinositides (IPr) were determined according to Ber- 
ridge et al. [ 191. Data represent averages of 2-5 experiments perform- 
ed in duplicate. Data were calculated and plotted with the aid of the 
EZ-FIT program (courtesy of Frank W. Perrella of E.I. DuPont de 
Nemours & Co.). 
3. RESULTS 
IPr formation in response to EGF was determined at 
different time intervals both in A43 1 and A43 l/Cl 15-2 
cells and was found to increase linearly up to 20 and 40 
min, respectively. In the A431/Clone 15-2 cells, IPr 
continued to rise for at least 10 h after EGF stimulation. 
[3H]PIP~ breakdown in response to EGF increased with 
EGF concentrations and was maximal at 100 ng/ml 
(not shown) and, therefore, this dose of the growth fac- 
tor was used in all subsequent experiments. 
The effect of tyrphostin AG 18 (3 ,Cdihydroxyben- 
zene malononitrile) on the response of PLC to EGF in 
A43 1 and A43 l/Cl 15-2 cells is compared in fig. 1. In 
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Fig. 1. The inhibition of PIPz hydrolysis by tyrphostin AGl8. The accumulation of inositol phosphates in the absence (a) and in the presence ( IJ ) 
of EGF and the net increase in response to EGF (A) in A431 cells (A and C) or A43l/Cll5-2 (B and D). 
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response to EGF, IPr increased 1 S-1 .&fold in A43 1 
cells and 3.0-fold or more in the A43l/CllS-2 cells. In 
both cell types, the tyrphostin inhibited ‘basal’ t3H]IPr 
formation as well as the EGF-stimulated activity (fig. 1). 
The I& for the inhibitory effect on the EGF- 
dependent 3H]IPr formation was found to be 14.5 FM 
for the parent cells (A431) and 18.2 FM for the 
A431/C115-2 cells. Similar behavior was found for a 
number of other tyrphostins (table 1). Fig.2 (A and B) 
shows the effect of tyrphostin AG18 on the [3H]IPr for- 
mation induced by Ca2+ ionophore A23 18’7 in A43 1 and 
A431/C115-2 cells. In both cell types, the effect of the 
tyrphostin was far greater on the EGF-dependent than 
on the Ca2+ ionophore-induced breakdown of PIP2. 
The discrepancy between the inhibitory effect of tyr- 
phostins on the EGF-dependent activity and Ca2’ 
ionophore-dependent activity was highest for the better 
inhibitors: AG18, AG213, AG99 and AG114; poor 
EGF receptor kinase inhibitors (AG115 and AG81) 
showed diminished discrimination (table 1). 
4. DISCUSSION 
Recent studies have shown that in response to EGF 
and PDGF, PLC-II becomes phosphorylated on 
tyrosine residues 112,131. In these studies the authors 
suggest that phosphorylation of PLC-II (PLC 7) in 
response to growth factor-receptor activation results in 
Table 1 
Inhibition of EGF dependent PIP2 hydrolysis by t~phostins 
Tyrphostin Inhibition of PIP2 Inhibition of EGFR-TK 
hydrolysis, ICSO GM) activity, ICSO GM) 
Structure No. EGF Ca’+ ionophore Poly-Gata Autophosp- 
-horylationb 
CN 
HO 
HO 
S 
HO 
HO 
0 
HO 
HO 
HO 
HO 
HO 
Me0 
HO 
Me0 
CN 
AG18 18.4 285.0 10.0 40.0 
AG213 19.6 XXl.0 1.8 
AG99 38.0 
AC114 55.0 
AG34 25.0 
AG115 66.0 
AG81 85.0 
2 100.0 12.5 4.0 
> 100.0 2.5 18 
58.0 6.0 20 
2285 200.0 - 
2 110.0 1250.0 - 
a Concentration needed to inhibit 50% of Poly(Glu,sAIasTyr) phosphorylation at substrate con- 
centration which equals WC,, as described in 1161 
b Inhibition of EGF receptor autophosphorylation, as described in [16,17] 
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Fig.2. The inhibition of PIP2 hydrolysis by tyrphostin AG18 in (A) A431 and (Bf A31/CIone 15-2 cells in response to EGF (+) or CaZf ionophore 
A23187 ( II ). %C = percent control. 
enzyme activation leading to the well documented 
growth factor-induced breakdown of PIP2 and Ca2+ 
mobilization [l-6,13]. In one of these studies 1131, it 
was shown that tyrphostin AG213 (table 1) inhibits the 
EGF-induced phosphorylation of PLC-II and the EGF- 
induced Ca2+ mobilization. In the current report we 
demonstrate that tyrphostins which are effective 
EGFR-kinase inhibitors are also effective in the inhibi- 
tion of EGF-dependent breakdown of PIP2. Further- 
more, the most potent tyrphostin inhibitors also inhibit 
the EGF-dependent IPT formation more potently than 
the EGF-independent activation of phospholip~e C in- 
duced by the Ca’+ ionophore A23 187. We were surpris- 
ed to find that tyrphostins actually inhibit basal PIP2 
breakdown. One possible explanation is that in cells 
which harbor an extremely high number of EGF recep- 
tors most of the PLC is physically associated with the 
receptor. Therefore, binding of tyrphostins to the EGF- 
receptor kinase substrate domain might affect the non- 
phosphorylated receptor-associated state of the en- 
zyme. Indeed, it was shown in a previous study that the 
phosphorylation-dependent association between the 
EGFR and PLC-II was blocked by AG213 [ 131. Thus, 
one may speculate that the basal activity of PLC within 
the EGFR-PLC-II complex is higher than the free form 
of PLC-II. It follows that at increasing tyrphostin con- 
centrations basal PLC activity is progressively inhibited 
concomitantly with the breakdown of the PLC-EGFR 
complex. It is likely that in cells which harbor a smaller 
number of EGF receptors, PLC is not associated with 
the growth factor receptor and, therefore, its activity 
should not be influenced by tyrphostins. In fact, in 
PC12 cells which harbor only 8.4x lo4 EGF recep- 
tors/cell and respond weakly to EGF [20-221, we could 
not detect EGF-stimulated PIP2 breakdown nor could 
we detect any effect of tyrphostins on PLC activity (un- 
published). 
The efficacy of AG213 is much lower in inhibiting 
EFG-induced breakdown of PIP2 than in inhibiting the 
phosphorylation of polyGAT (table 1). The ICSO for the 
290 
inhibition of PIP2 breakdown is in the same range as 
the IQ0 for the inhibition of the autophosphorylation 
of EGFR by the tyrphostin. This is not surprising, since 
the receptor and PLC-II (PLC r) are complexed with 
each other. The situation with AG81 seems to be revers- 
ed: the tyrphostin is a more effective inhibitor of PIP2 
hydrolysis in intact cells, although it is a poor inhibitor 
of phosphorylation of an exogenous ubstrate in vitro. 
This reverse discrepancy most probably results from the 
accumulation of the very hydrophobic AG81 in the cells 
much beyond the initial concentration of the compound 
in the medium. A similar situation was encountered 
with insulin receptor kinase where hydrophobic in- 
hibitors were found to be more effective in intact cells 
than in vitro 1231. In this case the hydrophobic com- 
pounds similarly accumulated inside the cells to concen- 
trations beyond those of the medium. 
In conclusion the observation that tyrphostins inhibit 
EGF-dependent PIP;? hydrolysis strengthens the 
hypothesis that the phosphorylation of PLC-II by 
EGFR leads to its activation [ 13,141. These studies as 
well as our previous reports [13,17,18,23] demonstrate 
the usefulness of tyrphostins as molecular tools for the 
dissection of the signals triggered by protein tyrosin 
kinases. 
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